Rebecca Jane Cox
Brokstad
Professor
Visit Address:
Haukeland universitetssykehus, Laboratoriebygget
5021 Bergen
Postal Address:
Postboks 7804
5021 Bergen
Phone:
+47 55 97 46 68
+47 452 42 974
E-mail:
Journal articles
- 2014. Divergent H7 immunogens offer protection from H7N9 virus challenge. Journal of Virology. 88: 3976-3985. doi: 10.1128/JVI.03095-13
- 2014. Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge. PLoS ONE. 9. doi: 10.1371/journal.pone.0093761
- 2014. Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: An explorative study. Multiple Sclerosis. 20: 1074-1080. doi: 10.1177/1352458513513970
- 2014. Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination. Vaccine. 32: 4550-4557. doi: 10.1016/j.vaccine.2014.06.009
- 2014. Experimental infection of healthy volunteers with enterotoxigenic Escherichia coli wild-type strain TW10598 in a hospital ward. BMC Infectious Diseases. 14. 9 pages. doi: 10.1186/1471-2334-14-482
- 2013. A(H1N1)pdm09 Vaccination of Healthcare Workers: Improved Immune Responses in Low Responders Following Revaccination Reply. Journal of Infectious Diseases. 207: 1186-1188. doi: 10.1093/infdis/jit014
- 2013. Correlates of protection to influenza virus, where do we go from here? Human Vaccines & Immunotherapeutics. 9: 405-408. doi: 10.4161/hv.22908
- 2012. The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants. Human Vaccines & Immunotherapeutics. 8: 653-661. doi: 10.4161/hv.19503
- 2012. A(H1N1)pdm09 Vaccination of Health Care Workers: Improved Immune Responses in Low Responders Following Revaccination. Journal of Infectious Diseases. 206: 1660-1669. doi: 10.1093/infdis/jis589
- 2012. The mucosal vaccine quandary Intranasal vs. sublingual immunization against influenza. Human Vaccines & Immunotherapeutics. 8: 690-694. doi: 10.4161/hv.19568
- 2012. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. Journal of Infectious Diseases. 206: 158-166. doi: 10.1093/infdis/jis330
- 2012. Influenza-like illness in general practice in Norway: clinical course and attitudes towards vaccination and preventive measures during the 2009 pandemic. Family Practice. 29: 139-146. Published 2011-09-05. doi: 10.1093/fampra/cmr064
- 2012. The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine. Influenza and Other Respiratory Viruses. 6: 90-100. doi: 10.1111/j.1750-2659.2011.00271.x
- 2011. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M (TM) adjuvant in a phase I clinical trial. Vaccine. 29: 8049-8059. doi: 10.1016/j.vaccine.2011.08.042
- 2011. Comparison of Different Routes of Administration for Influenza Vaccines in a Murine Model. Scandinavian Journal of Immunology. 73: 351-351.
- 2011. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4(+) cells and strong mucosal and systemic antibody responses in mice. Vaccine. 29: 4973-4982. doi: 10.1016/j.vaccine.2011.04.094
- 2011. Influenza Specific T-Cell Responses Predict Later Neutralizing Antibody Titres in a Phase 1 Clinical Trial of a Virosomal H5N1 Vaccine Adjuvanted with Matrix-M. Scandinavian Journal of Immunology. 73: 355-355.
- 2011. Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLoS ONE. 6. 12 pages. doi: 10.1371/journal.pone.0026973
- 2011. Pandemic Influenza Vaccination Elicits Influenza-Specific CD4(+) Th1-cell Responses in Hypogammaglobulinaemic Patients: Four case reports. Scandinavian Journal of Immunology. 74: 210-218. doi: 10.1111/j.1365-3083.2011.02561.x
- 2011. Pandemic influenza vaccination of hypogammaglobulinemic patients induces normal or elevated influenza-specific CD4+Th1-cell responses. Influenza and Other Respiratory Viruses. 5: 376-379.
- 2011. Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza and Other Respiratory Viruses. 5: 426-437. doi: 10.1111/j.1750-2659.2011.00256.x
- 2011. Lars R. Haaheim PhD (1945-2011) Obituary. Influenza and Other Respiratory Viruses. 5: 297-298. doi: 10.1111/j.1750-2659.2011.00281.x
- 2010. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine. 29: 266-273. doi: 10.1016/j.vaccine.2010.10.038
- 2009. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine. 27: 1889-1897. doi: 10.1016/j.vaccine.2009.01.116
- 2009. A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models. Influenza and Other Respiratory Viruses. 3: 107-117. doi: 10.1111/j.1750-2659.2009.00082.x
- 2009. The Immunogenicity of a Cell-derived H7N1 Split Influenza Virion Vaccine in Mice. Scandinavian Journal of Immunology. 69: 576-578. doi: 10.1111/j.1365-3083.2009.02254.x
- 2009. A pilot study of the immune response to whole inactivated avian influenza H7N1 virus vaccine in mice. Influenza and Other Respiratory Viruses. 3: 21-28. doi: 10.1111/j.1750-2659.2009.00075.x
- 2009. Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine. 27: 7367-7376. doi: 10.1016/j.vaccine.2009.09.044
- 2007. A comparison of the humoral and cellular immune responses at different immunological sites after split influenza virus vaccination of mice. Scandinavian Journal of Immunology. 65: 14-21. doi: 10.1111/j.1365-3083.2006.01862.x
- 2007. Quality and kinetics of the antibody response in mice after three different low-dose influenza virus vaccination strategies. Clinical and Laboratory Immunology. 14: 978-983. doi: 10.1128/CVI.00033-07
- 2007. Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients. The International Journal of Chronic Obstructive Pulmonary Disease. 2: 229-240.
- 2006. Pandernic influenza vaccine development: time is of the essence. Expert Review of Vaccines. 5: 603-606.
- 2006. Pandemic influenza vaccine development: time is of the essence. Expert Review of Vaccines. doi: 10.1586/14760584.5.5.603
- 2006. The humoral and cellular responses induced locally and systematically after parenteral influenza vaccination in man. Vaccine. 24: 6577-6580.
- 2006. The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice. Vaccine. 24: 6585-6587. doi: 10.1016/j.vaccine.2006.05.040
- 2006. Impact of influenza vaccine formulation with a detailed analysis of the cytokine response. Scandinavian Journal of Immunology. 64: 467-475. doi: 10.1111/j.1365-3083.2006.01805.x
- 2005. Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scandinavian Journal of Immunology. 62: 36-44.
- 2005. Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice. Scandinavian Journal of Immunology. 62: 342-352.
- 2004. Influenza virus: Immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scandinavian Journal of Immunology. 59: 1-15.
- 2002. Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. Journal of Infectious Diseases. 185: 878-884.
- 2002. Non-lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication. Scandinavian Journal of Immunology. 55: 14-23.
- 2001. High prevalence of influenza specific antibody secreting cells in nasal mucosa. Scandinavian Journal of Immunology. 54: 243-247.
- 2001. Non-lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication. Scandinavian Journal of Immunology. 55: 14-23.
- 2001. The effect of zanamivir treatment on the early immune response to influenza vaccination. Vaccine. 19: 4743-4749.
Book sections
- 2004. Comparison of the humoral immune response to split and whole virus vaccines in mice. Vaccines, pages 632-635. In:
- 2004. Options for the Control of Influenza V. 850 pages.
- 2004. The immune response to H7N1 whole virus vaccine in mice. Vaccines, pages 636-639. In:
- 2004. Options for the Control of Influenza V. 850 pages.
- 2004. The kinetics of the systemic and local immune response to parenteral influenza vaccination. International Series 1263, pages 515-518. In:
- 2004. Options for the Control of Influenza V. 850 pages.
- 2003. Detection of antibodies to influenza virus in human mucosal tissues and fluids. In:
- 2003. Methods in Molecular Medicine focusing on Methods in Viral Immunity.
More information in national current research information system (CRIStin)
